New drugs in cutaneous T-cell lymphomas.

Scarisbrick JJ1.

Abstract
PURPOSE OF REVIEW:
Currently, there are no curative therapies for cutaneous T-cell lymphoma (CTCL), and consecutive treatments tend to be given until loss of response. There is an urgent need for new and improved therapies in CTCL to treat symptoms such as pruritus and painful skin lesions and prolong survival. This article reviews new drugs available for CTCL.
RECENT FINDINGS:
CTCL encompasses a group of T-cell neoplasms presenting in the skin without systemic involvement. Mycosis fungoides being the most common type and Sézary syndrome the leukaemic form. Treatment is dependent on stage and responses to previous therapy. Treatments are broadly divided into skin-directed therapies which are first-line for early stage disease and systemic therapy reserved for refractory or advanced stage CTCL. This article reviews mode of action, responses and adverse effects of new drugs being considered for CTCL.
SUMMARY:
Most drugs for CTCL have response rates between 30 and 40%, and response durations tend to be less than a year. As such new studies looking at drug combinations or as maintenance therapy in those with a response to previous therapy should be trialled and may offer improved quality of life and outcome in CTCL.